Clinical Observation of Acupoint Injection with Salvia miltiorrhiza Injection in Patients with Facial Inflammatory Dermatosis

objective: To observe the clinical efficacy of Zusanli (ST36) acupoint injection of Salvia miltiorrhiza injection combined with conventional Western medicine in the treatment of facial inflammatory dermatosis (acne vulgaris and seborrheic dermatitis), and to systematically analyze the application value of combined injection of Salvia miltiorrhiza injection and Zusanli (ST36) acupoint injection in the treatment of facial inflammatory dermatosis by observing changes of the lesion severity before and after treatment and some relevant clinical efficacy indicators. Methods: A total of 69 patients with facial acne and seborrheic dermatitis admitted from 2025 to 2026 were enrolled and divided into a treatment group (n=39) and a control group (n=30) according to the treatment modality. The control group was treated with conventional Western pharmacotherapy only, and the treatment group was treated with the same conventional Western pharmacotherapy plus Zusanli acupoint injection of Salvia miltiorrhiza injection. The standard severity of facial skin lesions in two groups before and after treatment are scored. The change of severity of lesion score and the total clinical effective rate are applied as observation indexes. In each group, the treatment results were compared with the before-treatment period to study whether or not there was an advantage of synergistic effects of Chinese and Western medicine over the single conventional Western medicine treatment period. Results: Compared with the before-treatment period, the facial lesion severity scores in 2 groups were remarkably reduced in the after-treatment period with statistically significance differences within group (both P